toms, including immunodeficiency, hepatic and hematological disorders, and often leads to the development of malignant transformation of EBVinfected cells (2, 3) . In addition, EBVhas been reported to be associated with manymalignant diseases, not only Burkitt lymphoma, but nasopharyngeal carcinoma, Hodgkin's disease, gastric cancer, nasal NK/T cell lymphoma, malignant histiocytosis, and leiomyosarcoma ( 1-4).
EBVand Host ImmuneResponses
Whyis EBVassociated with this wide range of clinical diseases including malignant neoplasms? It is related to the specific features of EBVitself and the host immuneresponses to control EBVinfection. EBVinitially infects oropharyngeal epithelium and/or B cells, where propagation and complete maturation of EBVoccur. In addition, the oropharynx provides the main site for the persistent and latent infection of EBVin healthy individuals after recovery from primary EBV infection (1, 2) . EBValso infects B cells, and sometimes other lymphocytes, via CD21 (C3d receptor) and transforms B cells, expressing LYDMA, which mainly consists of latent membrane protein (LMP) and EBNA2 (1, 2 See also p 651.
FasL: Another Escape Mechanism from the ImmuneSystem of EBV
Furthermore, recently, accumulating evidence including the clinical report which appears in this issue, suggested that EBV infected cells express and release Fas ligand (FasL) (6, 7). Activated T cells express Fas on their surfaces, and will be killed by FasL, of which mechanism prevents the overshoot of immuneresponse (8) . The production of FasL in EBVinfected and/or transformed cells maycontribute to the increased survival of EBVtransformed cells evading from host immuneresponses, leading to the development of malignant neoplasms. However, recently, it was reported that RCAS1 (receptor-binding cancer antigen expressed on SiSo cells), which is a new apoptosis inducing factor against immunecells, rather than FasL was expressed in Reed-Sternberg cells in Hodgkin's disease in association with apoptotic lymphocytes surrounding ReedSternberg cells (9, 10 
